Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int Arch Allergy Immunol ; 181(12): 908-918, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32814335

RESUMEN

INTRODUCTION: Cow's milk allergy (CMA) is one of the most common food allergies especially early in life. A mixture of nondigestible short-chain galacto-oligosaccharides, long-chain fructo-oligosaccharides, and pectin-derived acidic-oligosaccharides (GFA) may reduce allergy development and allergic symptoms in murine CMA. Recently, vitamin D (VitD) has been suggested to have beneficial effects in reducing allergy as well. OBJECTIVE: In this study, the immune modulatory effect on allergy prevention using the combination of GFA and VitD was investigated. METHODS: Female C3H/HeOuJ mice were fed a control or GFA-containing diet with depleted, standard (1,000 IU/kg), or supplemented (5,000 IU/kg) VitD content for 2 weeks before and during whey sensitization (n = 10-15). Mice were sensitized 5 times intragastrically with PBS as a control, whey as cow's milk allergen, and/or cholera toxin as adjuvant on a weekly interval. One week after the last sensitization, mice were intradermally challenged in both ear pinnae and orally with whey, subsequently the acute allergic skin response and shock symptoms were measured. After 18 h, terminal blood samples, mesenteric lymph nodes, and spleens were collected. Whey-specific immunoglobulin (Ig) E and IgG1 levels were measured by means of ELISA. T cell subsets and dendritic cells (DCs) were studied using flow cytometry. RESULTS: Additional VitD supplementation did not lower the allergic symptoms compared to the standard VitD diet. CMA mice fed the GFA diet supplemented with VitD (GFA VitD+) significantly decreased the acute allergic skin response of whey sensitized mice when compared to the CMA mice fed VitD (VitD+) group (p < 0.05). The effect of GFA was not improved by extra VitD supplementation even though the CMA mice fed the GFA VitD+ diet had a significantly increased percentage of CD103+ DCs compared to the VitD+ group (p < 0.05). The VitD-deprived mice showed a high percentage of severe shock and many reached the humane endpoint; therefore, these groups were not further analyzed. CONCLUSIONS: High-dose VitD supplementation in mice does not protect against CMA development in the presence or absence of GFA.


Asunto(s)
Células Dendríticas/inmunología , Hipersensibilidad a la Leche/dietoterapia , Piel/patología , Linfocitos T Reguladores/inmunología , Vitamina D/uso terapéutico , Alérgenos/inmunología , Animales , Bovinos , Dieta , Suplementos Dietéticos , Modelos Animales de Enfermedad , Femenino , Humanos , Inmunoglobulina E/metabolismo , Ratones , Ratones Endogámicos C3H , Leche/inmunología , Oligosacáridos/uso terapéutico
2.
Front Immunol ; 9: 2419, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30405619

RESUMEN

Background: Dietary non-digestible galacto-oligosaccharides (GOS) suppress allergic responses in mice sensitized and challenged with house dust mite (HDM). Budesonide is the standard therapy for allergic asthma in humans but is not always completely effective. Aim: To compare the efficacy of budesonide or different doses of GOS alone or with a combination therapy of budesonide and GOS on HDM-allergic responses in mice. Methods:BALB/c mice were sensitized and challenged with HDM, while fed a control diet or a diet supplemented with 1 or 2.5 w/w% GOS, and either or not oropharyngeally instilled with budesonide. Systemic and local inflammatory markers, such as mucosal mast cell protease-1 (mMCP-1) in serum, pulmonary CCL17, CCL22, and IL-33 concentrations and inflammatory cell influx in the bronchoalveolar lavage fluid (BALF) were determined. Results: Budesonide or GOS alone suppressed the number of eosinophils in the BALF of HDM allergic mice whereas budesonide either or not combined with GOS lowered both eosinophil and lymphocyte numbers in the BALF of HDM-allergic mice. Both 1 w/w% and 2.5 w/w% GOS and/or budesonide suppressed serum mMCP-1 concentrations. However, budesonide nor GOS alone was capable of reducing Th2 driving chemokines CCL17, CCL22 and IL-33 protein levels in supernatants of lung homogenates of HDM allergic mice, whereas the combination therapy did. Moreover, IL-13 concentrations were only significantly suppressed in mice treated with budesonide while fed GOS. A similar tendency was observed for the frequency of GATA3+CD4+ Th2 and CD4+RORγt+ Th17 cells in the lungs of the allergic mice. Conclusion: Dietary intervention using GOS may be a novel way to further improve the efficacy of anti-inflammatory drug therapy in allergic asthma by lowering Th2 driving mediators and mast cell degranulation.


Asunto(s)
Antiinflamatorios/uso terapéutico , Asma/terapia , Budesonida/uso terapéutico , Hipersensibilidad/terapia , Pulmón/patología , Mastocitos/inmunología , Oligosacáridos/administración & dosificación , Células Th2/inmunología , Animales , Antígenos Dermatofagoides/inmunología , Degranulación de la Célula , Terapia Combinada , Citocinas/metabolismo , Suplementos Dietéticos , Modelos Animales de Enfermedad , Humanos , Ratones , Ratones Endogámicos BALB C , Pyroglyphidae/inmunología , Balance Th1 - Th2
3.
Eur J Pharmacol ; 668 Suppl 1: S117-23, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21810418

RESUMEN

Breast feeding is considered as the best nutrition for growth and development of an infant. Human milk consists of a unique combination of nutritional components each with different characteristics. Oligosaccharides or non-digestible carbohydrates as one of these components, are generally accepted to have a beneficial effect by selectively stimulating the growth and/or activity of one or a limited number of bacterial species. Recently more evidence is rising for direct effects of oligosaccharides on the immune system. Oligosaccharides often used as dietary supplements for their beneficial effects on the host and its immune system, are derived from nutritional sources. In this review we aim to summarize the pharmaceutical properties of these food-borne oligosaccharides early in life.


Asunto(s)
Carbohidratos de la Dieta/farmacología , Oligosacáridos/farmacología , Animales , Lactancia Materna , Humanos , Enfermedades del Sistema Inmune/dietoterapia , Enfermedades del Sistema Inmune/tratamiento farmacológico , Enfermedades del Sistema Inmune/prevención & control , Leche Humana/química , Simbióticos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA